SREBP2 confers ferroptosis resistance by targeting GPX4 in colorectal cancer
SREBP2 enhances ferroptosis resistance in CRC by upregulating GPX4, thereby contributing to tumor progression. Our findings highlight SREBP2 as a potential therapeutic target and provide a rationale for the development of SREBP2-targeted strategies in colorectal cancer.
Authors
- Jinchi Chen
- Zhao Li
- Siqi Wen
- Huage Zhong
- Man Zhang
- Dejun Liu
- Junfeng Yu
- Wei Jiang
- Bei Yi
- Rong Liang
- Min Lin
- Ruiqi Chen
Institutions
- Guangxi Medical University (CN)
- Guangxi Center for Disease Prevention and Control (CN)
- Tumor Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- APOPTOSIS
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1007/s10495-025-02209-7
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
- Guangxi Medical University